Generic molecule: lomitapide
Company: Aegerion Pharmaceuticals
Approval date: Dec. 24
The scoop: The FDA approved lomitapide at a crucial point for Aegerion ($AEGR); the company has been slowly growing its relatively small commerical operation and focuses its resources on this program alone. Aegerion will market the drug for patients suffering from the rare genetic disease homozygous familial hypercholesterolemia which can lead to fatal heart conditions; the drug will include a boxed warning of liver toxicity.